Pharmaceutical Technology on MSN9h
AstraZeneca and Alteogen agree on ALT-B4 platform tech
AstraZeneca has entered an exclusive licence agreement with Alteogen involving the latter’s ALT-B4 platform technology.
Clinical Trials Arena2h
Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients
The company plans to submit a Biologics Licence Application to the US Food and Drug Administration later in 2025 for its DMD ...
Pharmaceutical Technology8h
Health Canada approves Biogen’s Skyclarys for Friedreich’s ataxia
Health Canada has granted approval for Biogen’s Skyclarys to treat Friedreich’s ataxia (FA) in individuals aged 16 years and above.